RxDoctor Payments Data

Teri Lynn, PA

Physician Assistant · Provo, UTNPI 1225129976

Payments from drug & device makers

$4,318in general payments, 2019–2025

Across 238 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$755
  • Boston Scientific$500
  • Boehringer Ingelheim$464
  • Pfizer$395
  • Johnson & Johnson$350
  • Novartis$247
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$4,317100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,318 in reported general payments places this provider in the 90th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$55,105
Medicare patients
222
Services billed
1,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban203$186,413
EntrestoSacubitril/Valsartan46$49,873
XareltoRivaroxaban24$30,114
FarxigaDapagliflozin Propanediol16$15,884
Repatha SureclickEvolocumab18$10,100
Metoprolol Succinate289$4,681
Atorvastatin Calcium300$4,326
Rosuvastatin Calcium209$3,860
Ranolazine ErRanolazine22$2,113
Carvedilol162$1,924
Losartan Potassium146$1,890
ClopidogrelClopidogrel Bisulfate139$1,773
Potassium Chloride94$1,618
Ezetimibe50$1,346
Amlodipine Besylate151$1,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$395$186,413203 claims
NovartisEntresto$247$49,87346 claims
Johnson & JohnsonXarelto$350$30,11424 claims
AstraZenecaFarxiga$39$15,88416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Provo

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →